Drotrecogin alpha: a rational approach to the treatment of submassive pulmonary embolism?
Crit Care. 2011 Feb 22;15(1):123
Authors: Samama CM, Godier A
ABSTRACT: Combining therapeutic doses of low-molecular-weight heparins and increasing doses of recombinant activated protein C - Drotrecogin alpha (activated), or DAA - is of theoretical interest with regard to the control of coagulation activation. The study by Dempfle and colleagues presents new data showing that endogenous activated protein C levels do not increase in nonseptic patients with pulmonary embolism. However, the results of the addition of these two treatments are puzzling, leaving unresolved the questionable clinical relevance of this combination and the possible increase in bleeding risk.
PMID: 21345242 [PubMed - as supplied by publisher]